LONDON (Dec. 12, 2014) — Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.
In a statement issued on Thursday, the Hopitaux Universitaires de Geneve said the trial had been suspended “as a precautionary measure.” The study involving 59 people began in November.
Researchers reported four cases of mild joint pain in the hands and feet in people who got the shot 10 to 15 days earlier. Officials will stop giving the vaccine next week to get more data and liaise with others who are testing the vaccine in the US, Canada, Germany and Gabon.
The vaccine was developed by the Canadian government and is licensed to two US companies, NewLink and Merck.
The trial is scheduled to resume in January in Geneva. - Sunstar
- 21-day Quarantine for OFWs From Ebola-Hit Countries Stays
- Only 40 Percent of Ebola Funds Reached Target Countries - UN Study
- Liberia: Only 5 People Being Treated for Ebola in Country
- After Ebola, WHO to Set Up Contingency Fund, Develop ‘Surge Capacity’
- WHO Adopts Reforms to Repair Reputation After Bungling Ebola
- UN: Fight Against Ebola is Far From Won
- Ebola Virus Changes Over Time, May Thwart Drugs - Study
- Mali Government Declares Country Ebola-free
- Ebola Outbreak in West Africa Appears to be Slowing Down - UN
- China Sending Large Ebola Relief Team to West Africa